The U.S. Food and Drug Administration (FDA) has approved lenacapavir, a groundbreaking long-acting HIV prevention drug that provides near-complete protection with just two injections per year. Marketed under the brand name Yeztugo, this drug could be a game-changer in the fight against HIV—if its high cost doesn’t keep it out of reach for those who need it most.

Why Is Lenacapavir a Breakthrough?

Despite decades of progress in HIV treatment, more than a million people are newly infected each year, and an effective vaccine remains elusive. Existing prevention methods, like daily oral pre-exposure prophylaxis (PrEP) pills, have been effective but suffer from inconsistent usage. Many people struggle to take a pill every day, reducing real-world effectiveness.

Lenacapavir changes that. It’s a twice-yearly injection that has shown 99.9% efficacy in clinical trials, making it functionally similar to a highly effective vaccine.

Doctor: A Teaspoon Kills All Parasites In Your Body!

doctor: a teaspoon kills all parasites in your body!...

June 20, 2025

3:59 am

Lose 40 lbs by Consuming Before Bed for a Week

lose 40 lbs by consuming before bed for a week...

June 20, 2025

4:11 am

Varicose Veins Will Disappear in the Morning! Read!

varicose veins will disappear in the morning! read!...

June 20, 2025

3:49 am

Always look young. This product removes wrinkles instantly!

always look young. this product removes wrinkles instantly!...

June 20, 2025

4:07 am

What the Clinical Trials Showed

• Study 1 (Women in Sub-Saharan Africa): Over 2,000 participants, zero HIV infections—a 100% prevention rate, outperforming the daily pill Truvada.
• Study 2 (Men & Gender-Diverse Individuals): Over 2,000 participants, only two infections—a 99.9% prevention rate, again surpassing Truvada.

Side effects were mild, including injection site reactions, headache, and nausea. The results were so compelling that Science named lenacapavir its 2024 “Breakthrough of the Year.”

The Cost Problem: Will This Drug Actually Reach Those Who Need It?

While the science is revolutionary, pricing remains a major hurdle.

• The current list price for lenacapavir (when used as an HIV treatment) is $39,000 per year.
• Analysts estimate the preventive version (Yeztugo) could cost $25,000 annually in the U.S.
• By comparison, cabotegravir, another long-acting HIV prevention shot (administered every two months), costs tens of thousands per year and has seen limited global adoption due to cost.

Activists Demand Affordable Pricing

Public health experts argue that high prices could stall progress in ending the HIV epidemic.

Knee & Joint Pain Will Go Away if You Do This Every Morning!

knee & joint pain will go away if you do this every morning!...

June 20, 2025

3:55 am

If You Find Moles or Skin Tags on Your Body, Read About This Remedy

if you find moles or skin tags on your body, read about this remedy...

June 20, 2025

4:09 am

Do This Every Night and the Fungus Will Disappear in 5 Days

do this every night and the fungus will disappear in 5 days...

June 20, 2025

3:52 am

Tired of debt? Become a money magnet and leave poverty behind!

tired of debt? become a money magnet and leave poverty behind!...

June 20, 2025

3:55 am

• Andrew Hill (Liverpool University): Found that lenacapavir could be mass-produced for just $25 per person per year.
• Winnie Byanyima (U.N. Under-Secretary-General): Called excessive pricing “abhorrent,” stating, “We cannot end AIDS with medicines that are so costly.”

Gilead Sciences, the maker of Yeztugo, has not yet disclosed pricing but faces pressure to lower costs for widespread accessibility.

Political Challenges: Funding Cuts Threaten HIV Progress

The FDA’s approval comes as the Trump administration has slashed funding for HIV prevention and treatment programs, both in the U.S. and abroad. Without government support or affordable pricing, lenacapavir’s potential could be wasted.

The Bottom Line: A Major Step Forward—With Major Barriers

Lenacapavir is a scientific breakthrough, offering the most effective HIV prevention tool yet. But unless cost and accessibility issues are resolved, its impact may be limited.

For now, the question remains: Will this drug help end HIV, or will it only be available to those who can afford it?

This article Revolutionary New HIV Prevention Drug Offers 99.9% Protection—But Can Anyone Afford It? appeared first on BreezyScroll.

Read more on BreezyScroll.